atai Life Sciences announced the U.S. FDA cleared an Investigational New Drug (IND) to conduct a clinical drug-drug interaction (DDI) study of PCN-101 (R-ketamine). atai…
Awakn Life Sciences announced results from the controlled Phase II A/B trial evaluating Ketamine-Assisted Therapy for the treatment of Alcohol Use Disorder (AUD). Low doses…
Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite. By David Gosselin “Although this science…
Intra-Cellular Therapies announced the U.S FDA has approved Caplyta (lumateperone) the treatment of depressive episodes associated with bipolar I or II disorder in adults, as…
Douglas Pharmaceuticals announced positive top-line data from BEDROC, its Phase 2 study of R-107 (slow-release ketamine)) versus placebo for patients with treatment resistant depression (TRD).…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
